Relapsed nodular lymphocyte-predominant Hodgkin lymphoma presenting as severe paraneoplastic hepatitis: a case reportarticle Published on 2023-06-302024-09-05 Journal: Journal of Medical Case Reports [Category] update2024, [키워드] Case report Hepatitis Hodgkin lymphoma Nodular lymphocyte-predominant Hodgkin lymphoma Paraneoplastic hepatitis [DOI] 10.1186/s13256-023-04014-9 PMC 바로가기 [Article Type] article
Diagnostic and treatment dilemma during the coronavirus disease 2019 pandemic: a primary pulmonary lymphoma presenting as a cavitary mass in a patient with coronavirus disease 2019: a case reportCase Report Published on 2023-01-132024-09-05 Journal: Journal of Medical Case Reports [Category] update2024, [키워드] bronchoscopy Case report Cavitary pulmonary lesion COVID-19 Hodgkin lymphoma Percutaneous needle biopsy [DOI] 10.1186/s13256-022-03745-5 PMC 바로가기 [Article Type] Case Report
A successful initiation of treatment of Hodgkin’s lymphoma with adriamycin-bleomycin-vinblastine-dacarbazine dose reduction in a patient with fulminant hepatic failure and co-infection with human immunodeficiency virus and hepatitis BCase Reports Published on 2022-03-012023-06-13 Journal: Journal of Oncology Pharmacy Practice [Category] B형 간염, [키워드] adriamycin-bleomycin-vinblastine-dacarbazine regimen cholestatic jaundice hepatic failure Hodgkin lymphoma [DOI] 10.1177/10781552211040182 [Article Type] Case Reports
Impact of the first COVID-19 lockdown in Germany on the rate of acute infections during intensive chemotherapy for Hodgkin lymphomaOriginal Paper Published on 2022-02-192023-06-12 Journal: Infection [Category] MERS, [키워드] COVID-19 Hodgkin lymphoma Infection Prophylaxis [DOI] 10.1007/s15010-022-01765-3 PMC 바로가기 [Article Type] Original Paper
Immune biomarkers to predict SARS-CoV-2 vaccine effectiveness in patients with hematological malignancies혈액 악성 종양 환자의 SARS-COV-2 백신 효과를 예측하는 면역 바이오 마커Article Published on 2021-12-142022-11-09 Journal: Blood Cancer Journal [Category] SARS, 바이오마커, [키워드] age Antibody Response B-cell Biomarker CD21 CD4 CD8 cell types classical monocytes complementary control group COVID-19 vaccination COVID-19 vaccine disorder dysregulation Effectiveness effector memory Evidence evidence of Factor flow cytometry Frequency greater Haematological cancer Health care help hematological Hematological malignancies Hematological malignancy Hodgkin lymphoma IgA IgG IgM immune immune cell type immune cell types immune dysregulation immune profiling immunogenicity immunological Immunosuppression immunotype memory B cells monoclonal monoclonal gammopathies Monocytes multidimensional Neutrophils Patient patients peaked performed Peripheral blood Practitioner predict reduced SARS-CoV-2 vaccine significantly T cells Treatment Tumor Tumour immunology vaccination Vaccine Viral Viral antigen viral antigens [DOI] 10.1038/s41408-021-00594-1 PMC 바로가기 [Article Type] Article
Prolonged persistence of SARS-CoV-2 infection during A+AVD therapy for classical Hodgkin’s lymphoma: A case report고전적 호지킨 림프종에 대한 A+AVD 치료 중 SARS-CoV-2 감염의 장기간 지속: 증례 보고Case Reports Published on 2021-12-012022-09-11 Journal: Current problems in cancer [Category] 진단, 치료제, [키워드] A+AVD therapy (brentuximab vedotin, doxorubicin, vinblastine, and dacarbazine) acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 added afebrile antiviral therapy Asymptomatic brentuximab vedotin Case report Chain Reaction chest X-ray Ciclesonide classical Classical Hodgkin lymphoma Comorbidities complaint coronavirus coronavirus disease Coronavirus disease 2019 COVID-19 COVID-19 patient COVID-19 patients criteria dacarbazine diagnosed with COVID-19 discharge discharged disease Doxorubicin Favipiravir Fever Health Organization Hematologic malignancy Hodgkin lymphoma hospital Infection mandatory opacity Patient patient population PCR PCR test PCR tests persistence polymerase chain polymerase chain reaction positive Prolonged remained Remdesivir Remdesivir, RT-PCR respiratory respiratory status RT-PCR SARS-CoV-2 SARS-COV-2 infection severe acute respiratory syndrome Coronavirus the patient therapy Treatment vinblastine Viral virus WHO World Health Organization worsened [DOI] 10.1016/j.currproblcancer.2021.100739 PMC 바로가기 [Article Type] Case Reports
Anti-Angiogenic Agent Combined with Anti-PD-1 Immunotherapy Showed Activity in Patients With Classical Hodgkin Lymphoma Who Have Failed Immunotherapy: A Retrospective Case Report StudyArticle Published on 2021-11-262023-08-30 Journal: Frontiers in Immunology [Category] E형 간염, [키워드] anti-angiogenic agent apatinib camrelizumab Hodgkin lymphoma Immunotherapy PD-1 [DOI] 10.3389/fimmu.2021.727464 PMC 바로가기
Potential Molecular Mechanisms of Rare Anti-Tumor Immune Response by SARS-CoV-2 in Isolated Cases of Lymphomas림프종의 분리 된 경우에서 SARS-COV-2에 의한 희귀 항 종양 면역 반응의 잠재적 분자 메커니즘Article Published on 2021-09-252022-09-01 Journal: Viruses [Category] SARS, 유전자 메커니즘, 진단, [키워드] anti-tumor immune response anti-tumor immunotherapy Apoptosis approach B-cell binding binding site Cancer CD27 CD45 cell proliferation classical Complete Complete Remission complex component domain Extracellular follicular Follicular lymphoma gamma-tubulin ring complex Hodgkin lymphoma induce inhibit initial interact interacting residues internalization Isolated lymphoma lymphoproliferative disorders M pro M protein membrane microtubule molecular mechanism monoclonal antibodies monoclonal antibody motif NF-kB nivolumab nsp10 Nsp7 oncogenesis ORF3a ORF3a protein PD-1 Pembrolizumab Potential Protein Proteins receptor Remission reported response responsible SARS-CoV-2 SARS-COV-2 infection Signaling the SARS-CoV-2 therapeutic potential TRADD TUBG1 virus [DOI] 10.3390/v13101927 PMC 바로가기 [Article Type] Article
Real-world efficacy of brentuximab vedotin plus bendamustine as a bridge to autologous hematopoietic stem cell transplantation in primary refractory or relapsed classical Hodgkin lymphomaOriginal Article Published on 2020-08-032024-09-02 Journal: Annals of Hematology [Category] 대상포진, [키워드] autologous hematopoietic stem cell transplantation Bendamustine brentuximab vedotin Hodgkin lymphoma survival [DOI] 10.1007/s00277-020-04204-1 PMC 바로가기 [Article Type] Original Article
Fatigue level changes with time in long-term Hodgkin and non-Hodgkin lymphoma survivors: a joint EORTC-LYSA cross-sectional studyResearch Published on 2019-07-022024-09-02 Journal: Health and Quality of Life Outcomes [Category] 대상포진, [키워드] cross-sectional study fatigue Hodgkin lymphoma Long-term survivors Non-Hodgkin lymphomas [DOI] 10.1186/s12955-019-1186-x PMC 바로가기 [Article Type] Research